Company research
GH Research PLC
CIK 1855129Updated Nov 17, 2026
GHRS price & chart
Loading TradingView…
NASDAQ:GHRS on TradingView ↗About the company
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression. GH Research PLC’s initial focus is on developing its novel and proprietary mebufotenin therapies for the treatment of patients with TRD.
In the news
CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions ↗
Seeking Alpha
COMPASS Pathways rebounds on earnings after selloff driven by rival’s NDA submission ↗
GH Research Remains Undervalued Ahead Of Pivotal Phase III Program ↗
GH Research: 'Buy' GH001 TRD Advancement Presses On And Expansion Opportunities ↗
SEC disclosures
GH Research PLC IPO declared effective by SEC ↗
Recent filings
Financials
FY 2025 · USDSource
Source
Source
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Profit or LossUSD | -48,258,000Source | -38,961,000Source | -35,587,000Source | -22,456,000Source |
| Additional Financial Items | ||||
| AdjustmentsForFinanceCostsUSD | 463,000Source | 717,000Source | 723,000Source | — |
| AdjustmentsForFinanceIncomeUSD | 11,128,000Source | 9,873,000Source | 8,978,000Source | — |
| AdjustmentsForSharebasedPaymentsUSD | 8,504,000Source | 1,171,000Source | 2,291,000Source | 1,671,000Source |
| AdjustmentsForUnrealisedForeignExchangeLossesGainsUSD | -1,753,000Source | -2,129,000Source | 2,621,000Source | -7,176,000Source |
| GeneralAndAdministrativeExpenseUSD | 21,953,000Source | 15,296,000Source | 11,401,000Source | 10,070,000Source |
| IncreaseDecreaseInWorkingCapitalUSD | 3,094,000Source | -188,000Source | -1,645,000Source | -2,159,000Source |
| InterestPaidClassifiedAsOperatingActivitiesUSD | 639,000Source | 723,000Source | 648,000Source | 22,000Source |
| InterestReceivedClassifiedAsOperatingActivitiesUSD | 12,060,000Source | 7,076,000Source | 4,283,000Source | 500,000Source |
| PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivitiesUSD | 197,000Source | 304,000Source | 219,000Source | — |
| ProceedsFromIssuingSharesUSD | 0Source | 0Source | 15,000Source | 0Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Selling, General and Administrative ExpenseUSD | 21,953,000Source | 15,296,000Source | 11,401,000Source | 10,070,000Source |
| Additional Financial Items | ||||
| ApplicableTaxRatenumber | 0.13Source | 0.13Source | 0.13Source | 0.13Source |
| BasicEarningsLossPerShareUSD per share | -0.79Source | -0.75Source | -0.68Source | -0.43Source |
| DilutedEarningsLossPerShareUSD per share | -0.79Source | -0.75Source | -0.68Source | -0.43Source |
| EmployeeBenefitsExpenseUSD | 21,282,000Source | 12,036,000Source | 10,200,000Source | 6,390,000Source |
| ExpenseFromSharebasedPaymentTransactionsWithEmployeesUSD | 8,504,000Source | 1,171,000Source | 2,291,000Source | 1,671,000Source |
| FinanceCostsUSD | 463,000Source | 717,000Source | 723,000Source | 244,000Source |
| FinanceIncomeUSD | 11,128,000Source | 9,873,000Source | 8,978,000Source | 1,166,000Source |
| GeneralAndAdministrativeExpenseUSD | 21,953,000Source | 15,296,000Source | 11,401,000Source | 10,070,000Source |
| IncomeTaxExpenseContinuingOperationsUSD | 0Source | 0Source | 0Source | 0Source |
| InterestExpenseUSD | — | — | 63,000Source | 0Source |
| InterestExpenseOnLeaseLiabilitiesUSD | 35,000Source | 48,000Source | 100,000Source | — |
| PostemploymentBenefitExpenseDefinedContributionPlansUSD | 600,000Source | 300,000Source | 100,000Source | — |
| ProfitLossAttributableToOwnersOfParentUSD | -48,258,000Source | -38,961,000Source | -35,587,000Source | -22,456,000Source |
| ProfitLossBeforeTaxUSD | -48,258,000Source | -38,961,000Source | -35,587,000Source | -22,456,000Source |
| ProfitLossFromOperatingActivitiesUSD | -60,718,000Source | -50,312,000Source | -41,222,000Source | -30,554,000Source |
| ResearchAndDevelopmentExpenseUSD | 38,765,000Source | 35,016,000Source | 29,821,000Source | 20,484,000Source |
Offerings
Registration 333-295872
Filing attachments
ef20080548_ex99-1.htm · 6-K · 2026-11-13
Exhibit 99.1 GH RESEARCH PLC Unaudited condensed consolidated interim statement of comprehensive loss Three months ended Nine months ended September 30, September 30, September 30, …
Read attachment ↗ef20080548_ex99-2.htm · 6-K · 2026-11-13
Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS This management’s discussion and analysis is designed to provide you with a narrative explanation of our financial condition and results of operations. You should read this discussion and analysis in conjunction with our unaudited condensed consolidated interim financial statements, including the notes thereto, as of and for the three and nine months ended September 30, 2026. You should also read…
Read attachment ↗ef20075260_ex99-1.htm · 6-K · 2026-08-06
Exhibit 99.1 GH RESEARCH PLC Unaudited condensed consolidated interim statement of comprehensive loss Three months ended Six months ended June 30, June 30, June 30, …
Read attachment ↗ef20075260_ex99-2.htm · 6-K · 2026-08-06
Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS This management’s discussion and analysis is designed to provide you with a narrative explanation of our financial condition and results of operations. You should read this discussion and analysis in conjunction with our unaudited condensed consolidated interim financial statements, including the notes thereto, as of and for the three and six months ended June 30, 2026. You should also read this …
Read attachment ↗ef20075541_ex99-1.htm · 6-K · 2026-06-04
Exhibit 99.1 GH Research Announces Publication of Phase 2a Postpartum Depression Results Dublin, Ireland, June 4, 2026 - GH Research PLC (Nasdaq: GHRS) today announced the publication of the full results from its Phase 2a trial in postpartum depression (PPD) and the acceptance of two oral presentations at the 37th World Congress of Neuropsychopharmacology (CINP 2026). The peer-reviewed article, titled “Inhaled Mebufotenin (GH001) for Adult Patients with Postpartum Depression: A Phase 2a Open-…
Read attachment ↗ef20074384_ex99-1.htm · 6-K · 2026-05-21
Exhibit 99.1 Apparent sadness Reported sadness Concentration difficulty Lassitude Inability to feel Mean (SD) Change from Baseline in MADRS Anhedonia Factor Items at Day 8 Results Disposition and Baseline Characteristics Disposition and baseline characteristics are presented in Table 1 Mean (SD) total MADRS scores at baseline were 29.0 (5.4) for GH001 and 28.2 (4.6) for placebo. Baseline MADRS anhedonia factor scores were 17.6 (3.2) for GH001 and 17.4 (2.6) for placebo Table 1. Patient Disposit…
Read attachment ↗